1. What types of COVID-19 tests are available in 2026?

Modern diagnostics rest on two pillars: molecular NAAT tests (including RT-PCR) and rapid antigen tests (Ag-RDT). Under WHO guidelines issued in March 2026, member states now report surveillance data using both methods, fully integrated with influenza monitoring systems (GISRS).

Serological blood tests, which measure antibody levels, are still available but used primarily for population immunity studies rather than active infection diagnosis.

2. How should you prepare for a COVID-19 test?

For a nasopharyngeal swab to return an accurate result, you should avoid eating, drinking, brushing your teeth, chewing gum, using throat lozenges, or rinsing your nose with saline for at least 3 hours before your appointment.

Any substance introduced into the oral or nasal cavity before the test can contaminate the sample or dilute viral concentration, increasing the risk of a false-negative result. Always check whether your specific testing site has additional preparation requirements.

3. How long does it take to get COVID-19 test results?

Turnaround time varies by technology. Antigen tests typically produce results within 15 minutes, while RT-PCR results are usually available within 24 hours.

According to ECDC reports from April 2026, strong supply chain stability means most EU laboratories now consistently deliver molecular results within one working day. Serological (antibody) tests, which require a blood draw and laboratory processing, generally return results within 3 working days.

4. When is the best time to test after a COVID-19 exposure?

For people without symptoms, the optimal window for testing is 5 full days after the last contact with an infected person. Testing too early — immediately after exposure — frequently produces a negative result simply because the viral load has not yet reached the detection threshold.

5. Do current tests detect new variants like BA.3.2 and XFG?

Yes. Current diagnostic tests maintain high sensitivity against dominant Omicron lineages, including the JN.1 and BA.3.2 subvariants being monitored in 2026.

Genomic surveillance conducted by the CDC — including wastewater monitoring through the NWSS program — confirms that spike protein mutations in these variants do not meaningfully compromise the performance of commercially available antigen or molecular tests. BA.3.2, detected globally between November 2024 and February 2026, is reliably identified by standard laboratory protocols.

6. What are the current COVID-19 positivity rates?

Epidemiological data from April 2026 points to stable, low-level viral activity. Positivity rates in sentinel surveillance systems — for example, those tracked by UKHSA — are hovering around 1%, and SARS-CoV-2 now represents a small share of diagnosed respiratory infections overall.

In the United States, CDC and state-level reports such as those from KDHE indicate that COVID-19 accounted for approximately 0.3% of emergency department visits in March 2026. This stabilization reflects the high level of hybrid immunity in the general population, achieved through vaccination and prior infection.

As a result, mass testing has largely given way to targeted, sentinel-based diagnostic surveillance — a shift that represents the transition from crisis response to endemic disease management.

Frequently asked questions